Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population‐based registry in southwest Germany
Open Access
- 12 May 2020
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 27 (8), 1405-1414
- https://doi.org/10.1111/ene.14300
Abstract
Background A wide variety of metabolic changes, including an increased incidence of diabetes mellitus (DM) and dyslipidaemia, has been described in amyotrophic lateral sclerosis (ALS). The aim of this study was to investigate the associations of statin use and history of DM with onset of disease and survival in patients with ALS. Methods 501 patients (mean age: 65.2 ± 10.9 years; 58.5% male) from the ALS‐registry Swabia recruited between October 2010 and April 2016 were included in this prospective cohort study. Data were collected using a standardized questionnaire. Results Statin use (n=65) was not associated with overall survival (p=0.62). Age of ALS onset in patients with DM was 4.2 years (95% CI 1.3–7.2 years) later compared to patients without DM (p < 0.01). Overall survival of patients with hight body mass index at study entry (> 27.0 kg/m2 = upper quartile, n=127) was prolonged by more than five months compared to patients with low BMI (< 22.0 kg/m2 = lower quartile, n=123; p = 0.04). Conclusions This study supports the view that statin use is not associated with overall survival of ALS patients, suggesting that statins are not harmful and should not be discontinued in ALS. Furthermore, the delayed onset of ALS in patients with DM may mirror the potentially protective metabolic profile associated with type II DM. Consistently, this study provided further evidence that high BMI is a positive prognostic factor in ALS.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (577631)
This publication has 49 references indexed in Scilit:
- Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry SwabiaBMC Neurology, 2013
- Premorbid body mass index and risk of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2012
- A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral SclerosisPLOS ONE, 2012
- Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosisMuscle & Nerve, 2011
- Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron DisordersCirculation: Cardiovascular Quality and Outcomes, 2010
- Amyotrophic Lateral Sclerosis-Like Conditions in Possible Association with Cholesterol-Lowering DrugsDrug Safety, 2009
- Prognostic factors in ALS: A critical reviewAmyotrophic Lateral Sclerosis, 2009
- High metabolic level in patients with familial amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2009
- Statins, Neuromuscular Degenerative Disease and an Amyotrophic Lateral Sclerosis-Like SyndromeDrug Safety, 2007
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994